查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1882970

兒童疫苗市場規模、佔有率、成長及全球產業分析：按類型、應用和地區劃分的洞察與預測（2024-2032 年）

Pediatric Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 159 Pages | 商品交期: 請詢問到貨日

價格

兒童疫苗市場成長驅動因素

全球兒童疫苗市場正經歷強勁增長，這主要得益於兒童免疫計劃的擴展、政府支持的增加以及對疫苗可預防疾病的日益重視。根據本報告，兒童疫苗市場預計將在 2024 年達到 453.6 億美元，2025 年將成長至 468.6 億美元，並在 2032 年達到 950.4 億美元。這意味著 2025 年至 2032 年的複合年增長率 (CAGR) 將達到 10.6%。 2024 年，北美以 43.23% 的市佔率領先。這主要歸功於其強大的醫療保健體系、較高的疫苗接種率以及頻繁的新產品上市。

兒童疫苗在預防小兒麻痺、麻疹、瘧疾、肺炎球菌疾病和腮腺炎等危及生命的疾病以及增強兒童免疫力方面發揮著至關重要的作用。葛蘭素史克（GSK plc）、默克公司（Merck & Co., Inc.）和賽諾菲（Sanofi）等大型公司正在擴大產能以滿足不斷增長的全球需求，從而為市場提供了支持。各國政府和非營利組織不斷增加投資，旨在保護兒童免受疫苗可預防疾病的侵害，這進一步推動了市場擴張。例如，蓋茲基金會於2025年6月宣布，將在五年內投資16億美元，以支持全球疫苗免疫聯盟（Gavi）的全球免疫計畫。

市場動態

驅動因素

政府支持力度的加大和大規模兒童疫苗接種計劃是推動市場發展的關鍵因素。聯合國兒童基金會（UNICEF）和全球疫苗免疫聯盟（GAVI）等國際組織與各國政府合作，購買疫苗並提供免疫服務。例如，2025年1月，全球疫苗免疫聯盟（GAVI）報告稱，自2023年以來，聯合國兒童基金會已向17個非洲國家的兒童提供了超過980萬劑瘧疾疫苗。這代表著全球兒童疫苗接種計畫的擴展。

阻礙因素

儘管全球需求不斷增長，但疫苗猶豫仍然是許多中低收入國家廣泛採用疫苗的障礙。錯誤訊息、對醫療系統的不信任、文化障礙以及醫療設施的匱乏都促使了疫苗接種率低。 2019年，世界衛生組織將疫苗猶豫列為全球十大健康威脅之一，而自新冠疫情爆發以來，這種不信任程度進一步加劇。

機會

由於針對目前尚無核准疫苗的疾病的研發工作不斷推進，存在著巨大的機會。拉沙熱和產腸毒素大腸桿菌 (ETEC) 等高傳染性疾病持續影響成千上萬的兒童。根據美國國立衛生研究院 (NIH) 2024 年 2 月發布的報告，拉沙熱每年促使 5,000 人死亡，新增病例達 10 萬至 30 萬例，但目前尚無核准疫苗。這種未被滿足的需求正在推動全球疫苗研發管線的擴張。

挑戰

兒科疫苗市場面臨的一大挑戰是低收入地區缺乏冷鏈儲存和物流基礎設施。根據 "人人享有永續能源" (SEforALL) 2021 年發布的一份報告，由於供應鏈限制和冷藏設施不可靠，27 億人無法可靠地獲得疫苗，促使疫苗浪費和供應有限。

市場趨勢

最重要的趨勢之一是聯合疫苗在全球的推廣。這減少了兒童所需的注射次數，簡化了免疫接種程序，並提高了整體疫苗接種覆蓋率。例如，2025年7月，全球疫苗免疫聯盟（GAVI）在茅利塔尼亞和塞內加爾推出了六價疫苗，可預防六種疾病，取代了傳統的五價疫苗和小兒麻痺滅活疫苗（IPV）。

細分市場亮點

2024年，重組疫苗、結合疫苗和次單位疫苗因其高效性和監管支持而佔市場主導地位。減毒活疫苗、滅活疫苗、mRNA疫苗、病毒載體疫苗和類毒素疫苗也因強大的研發管線和不斷擴大的審批範圍而需求強勁。

依疾病類型劃分，由於麻疹、德國麻疹、小兒麻痺、人類乳突病毒（HPV）和流感的高感染率，病毒性疾病疫苗佔了最大的市場佔有率。隨著雅培公司於 2024 年推出 PneumoShield 14，預計細菌性疾病疫苗市場將穩定成長。

口服疫苗因其易於接種且適用於大規模疫苗接種計劃而佔市場主導地位，而注射疫苗則憑藉先進的給藥技術持續擴張。

區域展望

北美鞏固了其領先地位，預計 2024 年收入將達到 196.1 億美元，這主要得益於其強大的基礎設施和創新能力。歐洲維持較高的疫苗接種覆蓋率，但面臨供應缺口。同時，由於疾病爆發和疫苗需求不斷增長，預計亞太地區將實現最快增長。拉丁美洲和中東/非洲地區在世界衛生組織和全球疫苗免疫聯盟 (GAVI) 支持的計畫下繼續擴大規模。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵洞察

  • 主要國家和地區的監管環境
  • 主要國家和地區的疫苗接種覆蓋率
  • 主要國家和地區的政府兒童免疫計劃
  • 兒童疫苗市場的技術進步
  • 主要產業趨勢（併購、合作、新產品發表）等等）

第五章：全球兒童疫苗市場分析、洞察與預測（2019-2032）

  • 市場分析、洞察與預測 - 按類型劃分
    • 減毒活疫苗
    • 滅活​​疫苗
    • 重組/結合/次單位疫苗
    • mRNA疫苗
    • 病毒載體疫苗
    • 類毒素疫苗
    • 其他
  • 市場分析、洞察與預測 - 按疾病劃分
    • 病毒性疾病
      • 甲型肝炎
      • 肝炎B
      • 小兒麻痺
      • 呼吸道合胞病毒 (RSV)
      • 流感
      • 人類乳突病毒 (HPV)
      • 麻疹、腮腺炎、德國麻疹 (MMR)
      • 輪狀病毒
      • 帶狀皰疹
      • 其他
    • 細菌性疾病
      • 肺炎鏈球菌感染
      • 百白破疫苗 (DTP)
      • 腦膜炎雙球菌感染
      • 其他
  • 市場分析、洞察與預測 - 按給藥途徑
    • 口服
    • 腸外給藥
  • 市場分析、洞察與預測 - 按分銷管道
    • 醫院和零售藥局
    • 政府供應商
    • 其他
  • 市場分析、洞察與預測 - 按地區
    • 北部美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章：北美兒童疫苗市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲兒童疫苗市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞半島
    • 歐洲其他地區

第八章：亞太地區兒童疫苗市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章 拉丁美洲兒童疫苗市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第十章 中東與非洲兒童疫苗市場分析、洞察與預測（2019-2032）

  • 依國家/地區
    • 海灣合作委員會 (GCC)
    • 南非
    • 其他中東和非洲國家/地區

第十一章：競爭分析

  • 全球市佔率分析 (2024)
  • 公司簡介
    • 默克公司 (Merck & Co., Inc.)
    • 賽諾菲 (Sanofi)
    • 巴拉特生技公司 (Bharat Biotech)
    • 葛蘭素史克公司 (GSK plc.)
    • 中國科興生物 (SINOVAC)
    • 印度血清研究所 (Serum Institute of India Pvt. Ltd.)
    • 哈夫金生物製藥股份有限公司 (HAFFKINE BIO-PHARMACEUTICAL CORPORATION LTD.)
    • 帕納西亞生物技術公司 (Panacea Biotec)
    • Bio Farma
    • AJ Vaccines A/S
    • 北京生物製品研究所有限公司 (Beijing Institute of Biological Products Co., Ltd.)
Product Code: FBI113756

Growth Factors of pediatric vaccines Market

The global pediatric vaccines market is experiencing strong growth driven by rising childhood immunization programs, expanding government support, and increasing focus on vaccine-preventable diseases. According to the report, the pediatric vaccines market size stood at USD 45.36 billion in 2024, and is projected to increase to USD 46.86 billion in 2025, before reaching USD 95.04 billion by 2032, reflecting a robust CAGR of 10.6% from 2025 to 2032. In 2024, North America dominated the market with a 43.23% share, owing to strong healthcare systems, high immunization coverage, and frequent product launches.

Pediatric vaccines play a crucial role in strengthening immunity among children and preventing life-threatening diseases such as polio, measles, malaria, pneumococcal infections, mumps, and more. The market is supported by major companies- including GSK plc., Merck & Co., Inc., and Sanofi-that are expanding production capacity to meet rising global demand. Increasing government and nonprofit investments aimed at protecting children from vaccine-preventable diseases further fuel market expansion. For instance, in June 2025, the Gates Foundation invested USD 1.60 billion over five years to support Gavi's vaccination programs worldwide.

Market Dynamics

Drivers

Growing government support and large-scale childhood vaccination programs are major drivers of the market. International organizations such as UNICEF and GAVI collaborate with governments to procure vaccines and deliver immunization services. As an example, GAVI reported in January 2025 that since 2023, UNICEF has delivered over 9.8 million malaria vaccine doses to children across 17 African nations. This highlights the increasing scale of pediatric immunization initiatives globally.

Restraints

Despite strong worldwide demand, vaccine hesitancy continues to hinder adoption in many low- and middle-income countries. Misinformation, mistrust in healthcare systems, cultural barriers, and limited access to medical facilities contribute to low vaccination rates. WHO identified vaccine hesitancy as one of the top ten global health threats in 2019, and levels of mistrust have increased since the COVID-19 pandemic.

Opportunities

Significant opportunities exist through growing research and development initiatives targeting diseases that currently lack approved vaccines. Highly contagious diseases such as Lassa fever and Enterotoxigenic E. coli (ETEC) continue to affect thousands of children. As per a February 2024 NIH report, Lassa fever causes 5,000 deaths annually and accounts for 100,000-300,000 cases each year, with no approved vaccine available yet. This unmet need is encouraging global expansion of vaccine research pipelines.

Challenges

A major challenge for the pediatric vaccines market is the lack of cold chain storage and logistics infrastructure in low-income regions. According to a 2021 report by Sustainable Energy for All, 2.7 billion people lack dependable access to vaccines due to supply chain limitations and unreliable cold storage-leading to vaccine wastage and reduced accessibility.

Market Trends

One of the most significant trends is the increasing global shift toward combination vaccines, which reduce the number of injections children require, simplify immunization schedules, and improve overall vaccination coverage. For example, in July 2025, GAVI introduced a hexavalent vaccine in Mauritania and Senegal that protects against six diseases, replacing previous pentavalent and IPV vaccines.

Segmentation Highlights

The recombinant/conjugate/subunit vaccine type dominated the market in 2024 due to high effectiveness and regulatory support. Live attenuated, inactivated, mRNA, viral vector, and toxoid vaccines are also witnessing strong demand driven by robust research pipelines and expanding approvals.

By disease indication, viral disease vaccines held the largest share owing to the high prevalence of measles, rubella, polio, HPV, and influenza. Bacterial disease vaccines are set to grow steadily, supported by new launches like Abbott's PneumoShield 14 in 2024.

The oral route leads the market due to ease of administration and suitability for mass immunization programs, while parenteral vaccines continue to expand with advanced delivery technologies.

Regional Outlook

North America generated USD 19.61 billion in revenue in 2024, solidifying its leadership through strong infrastructure and innovation. Europe maintains high immunization rates but faces supply gaps, while Asia Pacific is expected to grow fastest due to rising disease outbreaks and vaccination demand. Latin America and the Middle East & Africa continue to expand through WHO and GAVI-supported programs.

Conclusion

With the market expected to rise from USD 45.36 billion in 2024 to USD 95.04 billion by 2032, the pediatric vaccines industry remains on a strong growth trajectory. Government funding, technological advancements, and expanding immunization programs will continue to drive global market momentum through 2032.

Segmentation By Type

  • Live Attenuated
  • Inactivated
  • Recombinant/Conjugate/Subunit
  • mRNA Vaccine
  • Viral Vectors Vaccines
  • Toxoid
  • Others

By Disease Indication

  • Viral Diseases
    • Hepatitis
    • Hepatitis A
    • Hepatitis B
    • Polio
    • RSV
    • Influenza
    • HPV
    • Measles/Mumps/Rubella
    • Rotavirus
    • Shingles (Herpes Zoster)
    • Others
  • Bacterial Diseases
    • Pneumococcal Diseases
    • DTP
    • Meningococcal Diseases
    • Others

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Region

  • North America (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country)
    • Germany
    • U.K
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country /sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country /sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country /sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Regulatory Scenarios, By Key Countries/Regions
  • 4.2. Vaccination Coverage- By Key Countries/ Regions
  • 4.3. Government Immunization Programs for Children- By Key Countries/ Regions
  • 4.4. Technological Advancements in Pediatric Vaccines Market
  • 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)

5. Global Pediatric Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Live Attenuated
    • 5.1.2. Inactivated
    • 5.1.3. Recombinant/Conjugate/Subunit
    • 5.1.4. mRNA Vaccine
    • 5.1.5. Viral Vectors Vaccines
    • 5.1.6. Toxoid
    • 5.1.7. Others
  • 5.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 5.2.1. Viral Diseases
      • 5.2.1.1. Hepatitis A
      • 5.2.1.2. Hepatitis B
      • 5.2.1.3. Polio
      • 5.2.1.4. RSV
      • 5.2.1.5. Influenza
      • 5.2.1.6. HPV
      • 5.2.1.7. MMR
      • 5.2.1.8. Rotavirus
      • 5.2.1.9. Shingles
      • 5.2.1.10. Others
    • 5.2.2. Bacterial Diseases
      • 5.2.2.1. Pneumococcal Diseases
      • 5.2.2.2. DTP
      • 5.2.2.3. Meningococcal Diseases
      • 5.2.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital & Retail Pharmacies
    • 5.4.2. Government Suppliers
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Pediatric Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Live Attenuated
    • 6.1.2. Inactivated
    • 6.1.3. Recombinant/Conjugate/Subunit
    • 6.1.4. mRNA Vaccine
    • 6.1.5. Viral Vectors Vaccines
    • 6.1.6. Toxoid
    • 6.1.7. Others
  • 6.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 6.2.1. Viral Diseases
      • 6.2.1.1. Hepatitis A
      • 6.2.1.2. Hepatitis B
      • 6.2.1.3. Polio
      • 6.2.1.4. RSV
      • 6.2.1.5. Influenza
      • 6.2.1.6. HPV
      • 6.2.1.7. MMR
      • 6.2.1.8. Rotavirus
      • 6.2.1.9. Shingles
      • 6.2.1.10. Others
    • 6.2.2. Bacterial Diseases
      • 6.2.2.1. Pneumococcal Diseases
      • 6.2.2.2. DTP
      • 6.2.2.3. Meningococcal Diseases
      • 6.2.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital & Retail Pharmacies
    • 6.4.2. Government Suppliers
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Pediatric Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Live Attenuated
    • 7.1.2. Inactivated
    • 7.1.3. Recombinant/Conjugate/Subunit
    • 7.1.4. mRNA Vaccine
    • 7.1.5. Viral Vectors Vaccines
    • 7.1.6. Toxoid
    • 7.1.7. Others
  • 7.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 7.2.1. Viral Diseases
      • 7.2.1.1. Hepatitis A
      • 7.2.1.2. Hepatitis B
      • 7.2.1.3. Polio
      • 7.2.1.4. RSV
      • 7.2.1.5. Influenza
      • 7.2.1.6. HPV
      • 7.2.1.7. MMR
      • 7.2.1.8. Rotavirus
      • 7.2.1.9. Shingles
      • 7.2.1.10. Others
    • 7.2.2. Bacterial Diseases
      • 7.2.2.1. Pneumococcal Diseases
      • 7.2.2.2. DTP
      • 7.2.2.3. Meningococcal Diseases
      • 7.2.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital & Retail Pharmacies
    • 7.4.2. Government Suppliers
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Pediatric Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Live Attenuated
    • 8.1.2. Inactivated
    • 8.1.3. Recombinant/Conjugate/Subunit
    • 8.1.4. mRNA Vaccine
    • 8.1.5. Viral Vectors Vaccines
    • 8.1.6. Toxoid
    • 8.1.7. Others
  • 8.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 8.2.1. Viral Diseases
      • 8.2.1.1. Hepatitis A
      • 8.2.1.2. Hepatitis B
      • 8.2.1.3. Polio
      • 8.2.1.4. RSV
      • 8.2.1.5. Influenza
      • 8.2.1.6. HPV
      • 8.2.1.7. MMR
      • 8.2.1.8. Rotavirus
      • 8.2.1.9. Shingles
      • 8.2.1.10. Others
    • 8.2.2. Bacterial Diseases
      • 8.2.2.1. Pneumococcal Diseases
      • 8.2.2.2. DTP
      • 8.2.2.3. Meningococcal Diseases
      • 8.2.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital & Retail Pharmacies
    • 8.4.2. Government Suppliers
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Pediatric Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Live Attenuated
    • 9.1.2. Inactivated
    • 9.1.3. Recombinant/Conjugate/Subunit
    • 9.1.4. mRNA Vaccine
    • 9.1.5. Viral Vectors Vaccines
    • 9.1.6. Toxoid
    • 9.1.7. Others
  • 9.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 9.2.1. Viral Diseases
      • 9.2.1.1. Hepatitis A
      • 9.2.1.2. Hepatitis B
      • 9.2.1.3. Polio
      • 9.2.1.4. RSV
      • 9.2.1.5. Influenza
      • 9.2.1.6. HPV
      • 9.2.1.7. MMR
      • 9.2.1.8. Rotavirus
      • 9.2.1.9. Shingles
      • 9.2.1.10. Others
    • 9.2.2. Bacterial Diseases
      • 9.2.2.1. Pneumococcal Diseases
      • 9.2.2.2. DTP
      • 9.2.2.3. Meningococcal Diseases
      • 9.2.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital & Retail Pharmacies
    • 9.4.2. Government Suppliers
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Pediatric Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Live Attenuated
    • 10.1.2. Inactivated
    • 10.1.3. Recombinant/Conjugate/Subunit
    • 10.1.4. mRNA Vaccine
    • 10.1.5. Viral Vectors Vaccines
    • 10.1.6. Toxoid
    • 10.1.7. Others
  • 10.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 10.2.1. Viral Diseases
      • 10.2.1.1. Hepatitis A
      • 10.2.1.2. Hepatitis B
      • 10.2.1.3. Polio
      • 10.2.1.4. RSV
      • 10.2.1.5. Influenza
      • 10.2.1.6. HPV
      • 10.2.1.7. MMR
      • 10.2.1.8. Rotavirus
      • 10.2.1.9. Shingles
      • 10.2.1.10. Others
    • 10.2.2. Bacterial Diseases
      • 10.2.2.1. Pneumococcal Diseases
      • 10.2.2.2. DTP
      • 10.2.2.3. Meningococcal Diseases
      • 10.2.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Parenteral
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital & Retail Pharmacies
    • 10.4.2. Government Suppliers
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. Merck & Co., Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Sanofi.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Bharat Biotech.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. GSK plc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. SINOVAC
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Serum Institute of India Pvt. Ltd.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. HAFFKINE BIO-PHARMACEUTICAL CORPORATION LTD.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Panacea Biotec
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Bio Farma
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. AJ Vaccines A/S
      • 11.2.10.1. Overview
      • 11.2.10.2. Products & services
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)
    • 11.2.11. Beijing Institute of Biological Products Co., Ltd.
      • 11.2.11.1. Overview
      • 11.2.11.2. Products & services
      • 11.2.11.3. SWOT Analysis
      • 11.2.11.4. Recent Developments
      • 11.2.11.5. Strategies
      • 11.2.11.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Type, 2019-2032
  • Table 2: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Disease Indication, 2019-2032
  • Table 3: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Viral Diseases, 2019-2032
  • Table 4: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Bacterial Diseases, 2019-2032
  • Table 5: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 6: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
  • Table 7: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Region, 2019-2032
  • Table 8: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Type, 2019-2032
  • Table 9: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Disease Indication, 2019-2032
  • Table 10: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Viral Diseases, 2019-2032
  • Table 11: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Bacterial Diseases, 2019-2032
  • Table 12: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 13: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
  • Table 14: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 15: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Type, 2019-2032
  • Table 16: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Disease Indication, 2019-2032
  • Table 17: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Viral Diseases, 2019-2032
  • Table 18: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Bacterial Diseases, 2019-2032
  • Table 19: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 20: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
  • Table 21: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 22: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Type, 2019-2032
  • Table 23: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Disease Indication, 2019-2032
  • Table 24: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Viral Diseases, 2019-2032
  • Table 25: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Bacterial Diseases, 2019-2032
  • Table 26: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 27: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
  • Table 28: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 29: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Type, 2019-2032
  • Table 30: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Disease Indication, 2019-2032
  • Table 31: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Viral Diseases, 2019-2032
  • Table 32: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Bacterial Diseases, 2019-2032
  • Table 33: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 34: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
  • Table 35: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 36: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Type, 2019-2032
  • Table 37: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Disease Indication, 2019-2032
  • Table 38: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Viral Diseases, 2019-2032
  • Table 39: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Bacterial Diseases, 2019-2032
  • Table 40: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 41: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
  • Table 42: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Pediatric Vaccines Market Revenue Breakdown (USD billion, %), By Region, 2024 & 2032
  • Figure 2: Global Pediatric Vaccines Market Value Share (%), By Type, 2024 & 2032
  • Figure 3: Global Pediatric Vaccines Market Value Share (%), By Disease Indication, 2024 & 2032
  • Figure 4: Global Pediatric Vaccines Market Value Share (%), By Route of Administration, 2024 & 2032
  • Figure 5: Global Pediatric Vaccines Market Value Share (%), By Distribution Channel, 2024 & 2032
  • Figure 6: Global Pediatric Vaccines Market Value Share (%), By Region, 2024 & 2032
  • Figure 7: North America Pediatric Vaccines Market Value (USD billion), By Type, 2024 & 2032
  • Figure 8: North America Pediatric Vaccines Market Value Share (%), By Type, 2024
  • Figure 9: North America Pediatric Vaccines Market Value (USD billion), By Disease Indication, 2024 & 2032
  • Figure 10: North America Pediatric Vaccines Market Value Share (%), By Disease Indication, 2024
  • Figure 11: North America Pediatric Vaccines Market Value (USD billion), By Route of Administration, 2024 & 2032
  • Figure 12: North America Pediatric Vaccines Market Value Share (%), By Route of Administration, 2024
  • Figure 13: North America Pediatric Vaccines Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 14: North America Pediatric Vaccines Market Value Share (%), By Distribution Channel, 2024
  • Figure 15: North America Pediatric Vaccines Market Value (USD billion), By Country, 2024 & 2032
  • Figure 16: North America Pediatric Vaccines Market Value Share (%), By Country, 2024
  • Figure 17: Europe Pediatric Vaccines Market Value (USD billion), By Type, 2024 & 2032
  • Figure 18: Europe Pediatric Vaccines Market Value Share (%), By Type, 2024
  • Figure 19: Europe Pediatric Vaccines Market Value (USD billion), By Disease Indication, 2024 & 2032
  • Figure 20: Europe Pediatric Vaccines Market Value Share (%), By Disease Indication, 2024
  • Figure 21: Europe Pediatric Vaccines Market Value (USD billion), By Route of Administration, 2024 & 2032
  • Figure 22: Europe Pediatric Vaccines Market Value Share (%), By Route of Administration, 2024
  • Figure 23: Europe Pediatric Vaccines Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 24: Europe Pediatric Vaccines Market Value Share (%), By Distribution Channel, 2024
  • Figure 25: Europe Pediatric Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 26: Europe Pediatric Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 27: Asia Pacific Pediatric Vaccines Market Value (USD billion), By Type, 2024 & 2032
  • Figure 28: Asia Pacific Pediatric Vaccines Market Value Share (%), By Type, 2024
  • Figure 29: Asia Pacific Pediatric Vaccines Market Value (USD billion), By Disease Indication, 2024 & 2032
  • Figure 30: Asia Pacific Pediatric Vaccines Market Value Share (%), By Disease Indication, 2024
  • Figure 31: Asia Pacific Pediatric Vaccines Market Value (USD billion), By Route of Administration, 2024 & 2032
  • Figure 32: Asia Pacific Pediatric Vaccines Market Value Share (%), By Route of Administration, 2024
  • Figure 33: Asia Pacific Pediatric Vaccines Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 34: Asia Pacific Pediatric Vaccines Market Value Share (%), By Distribution Channel, 2024
  • Figure 35: Asia Pacific Pediatric Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 36: Asia Pacific Pediatric Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 37: Latin America Pediatric Vaccines Market Value (USD billion), By Type, 2024 & 2032
  • Figure 38: Latin America Pediatric Vaccines Market Value Share (%), By Type, 2024
  • Figure 39: Latin America Pediatric Vaccines Market Value (USD billion), By Disease Indication, 2024 & 2032
  • Figure 40: Latin America Pediatric Vaccines Market Value Share (%), By Disease Indication, 2024
  • Figure 41: Latin America Pediatric Vaccines Market Value (USD billion), By Route of Administration, 2024 & 2032
  • Figure 42: Latin America Pediatric Vaccines Market Value Share (%), By Route of Administration, 2024
  • Figure 43: Latin America Pediatric Vaccines Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 44: Latin America Pediatric Vaccines Market Value Share (%), By Distribution Channel, 2024
  • Figure 45: Latin America Pediatric Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 46: Latin America Pediatric Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 47: Middle East & Africa Pediatric Vaccines Market Value (USD billion), By Type, 2024 & 2032
  • Figure 48: Middle East & Africa Pediatric Vaccines Market Value Share (%), By Type, 2024
  • Figure 49: Middle East & Africa Pediatric Vaccines Market Value (USD billion), By Disease Indication, 2024 & 2032
  • Figure 50: Middle East & Africa Pediatric Vaccines Market Value Share (%), By Disease Indication, 2024
  • Figure 51: Middle East & Africa Pediatric Vaccines Market Value (USD billion), By Route of Administration, 2024 & 2032
  • Figure 52: Middle East & Africa Pediatric Vaccines Market Value Share (%), By Route of Administration, 2024
  • Figure 53: Middle East & Africa Pediatric Vaccines Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 54: Middle East & Africa Pediatric Vaccines Market Value Share (%), By Distribution Channel, 2024
  • Figure 55: Middle East & Africa Pediatric Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 56: Middle East & Africa Pediatric Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 57: Global Pediatric Vaccines Market Share (%), By Company, 2024